Advertisement PBR Staff Writer, Author at Pharmaceutical Business review - Page 435 of 4440
Pharmaceutical Business review is using cookies

ContinueLearn More
Close
 

All articles by  

UCB obtains access to antibody program from WILEX

Under the deal, UCB gains rights to develop the antibodies from the program for non-oncology indications such as immunology/inflammation, while WILEX holds rights to develop antibodies for oncology

Dipexium obtains new US patent for Locilex

Consisting 1% of pexiganan acetate cream, Locilex is an antibiotic peptide formulated as a topical cream and is used for the treatment of skin or wound infections. Dipexium